An Open-Label Phase II Study in Subjects With Recurrent EGFR-Positive Ovarian Cancer to Investigate the Safety and Efficacy of EMD 72000 Administered as a Single Agent

Inclusion Criteria:

- Recurrent ovarian cancer (including primary peritoneal cancer) following treatment
(e.g., doxorubicin HCL liposome, topotecan, etc.) for primary or secondary
platinum-refractory disease

- Immunohistochemical evidence of tumor EGFR (HER-1) expression

- At least one measurable lesion according to the WHO criteria

- Life expectancy ≥ 12 weeks

- ECOG performance status 0-1

Exclusion Criteria:

- History of prior MAb therapy

- History of prior treatment with an EGFR (HER-1) directed therapy

- Known brain metastases

- Presence of a ≥ Grade 2 pre-existing skin disorder (alopecia is permitted)

- Known intercurrent infections or immunosuppression

- Actively infected with, or chronic carriers of HBV

- Evidence of HCV disease

- Previous diagnosis of autoimmune disease

- Known hypersensitivity to the administered drugs or any of their components

- Receipt of chemotherapy, radiation therapy, or another investigational drug within 30
days of enrollment